Manish Goyal, MD
Hospitalist · Charlotte, NCNPI 1710220389
Payments from drug & device makers
Across 92 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$245
- AstraZeneca$216
- Novartis$206
- ANI Pharmaceuticals, Inc.$162
- Calliditas Therapeutics US Inc.$160
- Akebia Therapeutics Inc$142
- plus $800 from 14 others
What the payments were for
- Food & beverage$1,87297%
- Education$583%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 12 | $245 |
| AstraZeneca | 11 | $216 |
| Novartis | 9 | $206 |
| ANI Pharmaceuticals, Inc. | 7 | $162 |
| Calliditas Therapeutics US Inc. | 6 | $160 |
| Akebia Therapeutics Inc | 7 | $142 |
| Otsuka America Pharmaceutical, Inc. | 5 | $114 |
| Mallinckrodt Hospital Products Inc. | 4 | $88 |
| Ardelyx, Inc. | 3 | $84 |
| Vifor Pharma, Inc. | 4 | $84 |
| Amgen(2 entities) | 5 | $84 |
| Boehringer Ingelheim | 3 | $80 |
| GSK | 4 | $80 |
| Aurinia Pharma U.S., Inc. | 3 | $55 |
| Mallinckrodt Enterprises LLC | 3 | $45 |
| OPKO Pharmaceuticals, LLC | 2 | $31 |
| Johnson & Johnson | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
How this compares
$1,930 in reported general payments places this provider in the 80th percentile of 879 hospitalist providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 16 | $21,874 |
| Febuxostat | 14 | $1,576 |
| Lisinopril | 43 | $559 |
| Amlodipine Besylate | 109 | $511 |
| Calcitriol | 21 | $478 |
| Quetiapine Fumarate | 19 | $337 |
| Furosemide | 52 | $312 |
| Allopurinol | 44 | $305 |
| Torsemide | 11 | $305 |
| Omeprazole | 13 | $271 |
| Hydralazine Hcl | 19 | $220 |
| Metoprolol Succinate | 16 | $219 |
| Losartan Potassium | 22 | $216 |
| Metoprolol Tartrate | 19 | $168 |
| Atenolol | 14 | $144 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Charlotte
- Jenna BrooksCharlotte$24K
- Javad MonzavifarCharlotte$12K
- Bikki GautamCharlotte$12K
- Jorge PaulinoCharlotte$12K
- Emmett StewardCharlotte$11K
- Tabita MorrisCharlotte$11K
- Samyak ManandharCharlotte$11K
- David HendersonCharlotte$10K
- Amsalu BizunehCharlotte$9K
- Harsha AlluCharlotte$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.